Guillain-Barre syndrome

Lancet

Volumn 352, Issue 9128, 1998, Pages 635-641

  Hahn, Angelika F ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GANGLIOSIDE; IMMUNOGLOBULIN G; MYELIN;

ARTICLE; ASSISTED VENTILATION; AUTOIMMUNE DISEASE; CAMPYLOBACTER JEJUNI; CELLULAR IMMUNITY; DEMYELINATING NEUROPATHY; GASTROENTERITIS; GUILLAIN BARRE SYNDROME; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; INTENSIVE CARE; INTUBATION; NERVE FIBER MEMBRANE; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; SCHWANN CELL; CROSS REACTION; FEMALE; GRAM NEGATIVE INFECTION; IMMUNOLOGY; MALE; POLYRADICULONEUROPATHY; REVIEW;

AUTOIMMUNE DISEASES; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; CROSS REACTIONS; EPITOPES; FEMALE; HUMANS; MALE; POLYRADICULONEUROPATHY;

EID: 0032558184     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)12308-X     Document Type: Review

References (74)

1. 1 Olivé J-M, Castillo C, Garcia Castro R, de Quadros CA. Epidemiologic studyof Guillain-Barré syndrome in children < 15 years of age in Latin America. J Infect Dis 1997; 175 (suppl 1): S160-64.
2. 2 Giovannoni G, Hartung H-P. The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome. Curr Opin Neurol 1996; 9: 165-77.
3. 3 Asbury AK, Arnason BGW, Karp HR, McFarlin DF. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol 1998; 3: 565-66.
4. 4 Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27 (suppl): S21-24.
5. 5 Jiang GX, Cheng Qi, Link H, de Pedro-Cuesta J. Epidemiological features of Guillain-Barré syndrome in Sweden, 1978-93. J Neurol Neurosurg Psychiatry 1997; 62: 447-53.
6. 6 Beghi E, Kurland LT, Mulder DW, Wiederholt WC. Guillain-Barré syndrome: clinico-epidemiologic features and effect of influenza vaccine. Arch Neurol 1985; 42: 1053-57.
7. 7 Govoni V, Granieri E, Casetta I, et al. The incidence of Guillain-Barré syndrome in Ferrara, Italy: is the disease really increasing? J Neurol Sci 1996; 137: 62-68.
8. 8 Kaplan JE, Schonberger LB, Hurwitz ES, Katona P. Guillain-Barré syndrome in the United States, 1978-1981: additional observations from the national surveillance system. Neurology 1983; 33: 633-37.
9. 9 Visser LH, van der Meché FGA, Meulstee J, et al. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Neurology 1996; 47: 668-73.
10. 10 Blaser MJ. Epidemiologic and clinical features of Campylobacter jejuni infections. J Infect Dis 1997; 176 (suppl 2): S103-05.
11. 11 Prevots DR, Sutter RW. Assessment of Guillain-Barré syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J Infect Dis 1997; 175 (suppl 1): 151-55.
12. 12 Winer JB, Hughes RAC, Anderson MJ, et al. A prospective study of acute idiopathic neuropathy: II antecedent events. J Neurol Neurosurg Psychiatry 1988; 51: 613-18.
13. 13 Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995; 333: 1374-79.
14. 1 antibodies in Guillain-Barré syndrome. Ann Neurol 1996; 40: 181-87.
15. 15 Mishu B, Ilyas AA, Koski CL, et al. Serologic evidence of previous Campylobacter jejuni infection in patients with the Guillain-Barré syndrome. Ann Intern Med 1993; 118: 947-53.
16. 16 Kuroki S, Saida T, Nukina M, et al. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain β-N-acetylglucosamine residues. Ann Neurol 1993; 33: 243-47.
17. 17 Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationships to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995; 118: 597-605.
18. 18 Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255: 57-65.
19. 19 Jacobs BC, Endtz HPh, Van der Meché FGA, et al. Serum anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann Neurol 1995; 37: 260-64.
20. 20 Walsh FS, Cronin M, Koblar S, et al. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome. J Neuroimmunol 1991; 34: 43-51.
21. 1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995; 38: 809-16.
22. 22 Chiba A, Kusonoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992; 31: 677-79.
23. 23 Willison HJ, Veitch J, Paterson G, Kennedy PGE. Miller Fisher syndrome is associated with serum antibodies to GB1b ganglioside. J Neurol Neurosurg Psychiatry 1993; 56: 204-06.
24. 1 ganglioside-like structure. J Exp Med 1993; 178: 1771-75.
25. 1 and lipopolysaccharide from Penner's serotype 19 of Campylobacter jenuni. Biomed Res 1992; 13: 451-53.
26. 26 Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalomoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993; 43: 1911-17.
27. 27 Boucquey D, Sindic CJM, Lamy M, et al. Clinical and serological studies in a series of 45 patients with Guillain-Barré syndrome. J Neurol Sci 1991; 104: 56-63.
28. 28 Ogawa-Goto K, Kubota K, Kurotani A, Abe T. Antibodies against sulfated glycosphingolipids of peripheral nerve myelins detected in patients with human cytomegalovirus infection. J Neuroimmunol 1994; 55: 55-60.
29. 2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. J Neuroimmunol 1996; 68: 19-26.
30. 2 antibodies in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1997; 62: 641-43.
31. 31 Berger JR, Difini JA, Swerdloff MA, Ayyar DR. HIV seropositivity in Guillain-Barré syndrome. Ann Neurol 1987; 22: 393-94.
32. 32 Hemachudha T, Griffin DE, Chen WW, Johnson RT. Immunologic studies of rabies vaccination-induced Guillain-Barré syndrome. Neurology 1988; 38: 375-78.
33. 33 Safranek TJ, Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Am J Epidemiol 1991; 133: 940-51.
34. 34 Roscelli JD, Bass JW, Pang L. Guillain-Barré syndrome and influenza vaccination in the US Army, 1980-1988. Am J Epidemiol 1991; 133: 952-55.
35. 35 Kinnunen E, Junttila O, Haukka J, Hovi T. Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barré syndrome. Am J Epidemiol 1998; 147: 69-73.
36. 36 Salisbury DM. Association between oral poliovaccine and Guillain-Barré syndrome? Lancet 1998; 351: 79-80.
37. 37 Da Silveira CM, Salisbury DM, De Quadros CA. Measles vaccination and Guillain-Barré syndrome. Lancet 1997; 349: 14-15.
38. 38 Hughes R, Rees J, Smeeton N, Winer J. Vaccines and Guillain-Barré syndrome. BMJ 1996; 312: 1475-76.
39. 39 Brown WF, Feasby TE. Conduction block and denervation in Guillain-Barré polyneuropathy. Brain 1984; 107: 219-39.
40. 40 Honavar M, Tharakan JHJ, Hughes RAC, et al. A clinico-pathological study of the Guillain-Barré syndrome: nine cases and literature review. Brain 1991; 114: 1245-69.
41. 41 Griffin JW, Li CY, Ho TW, et al. Guillain-Barré syndrome in northern China: the spectrum of neuropathological changes in clinically defined cases. Brain 1995; 118: 577-95.
42. 42 Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996; 39: 625-35.
43. 43 Gregson NA, Koblar S, Hughes RAC. Antibodies to gangliosides in Guillain-Barré syndrome: specificity and relationship to clinical features. QJM 1993; 86: 111-17.
44. 44 Fuller GN, Jacobs JM, Lewis PD, Lane RJM. Pseudoaxonal Guillain-Barré syndrome: severe demyelination mimicking axonopathy: a case with pupillary involvement. J Neural Neurosurg Psychiatry 1992; 55: 1079-83.
45. 45 Berciano J, Figols J, Garcia A, et al. Fulminant Guillain-Barré syndrome with universal inexcitability of peripheral nerves: a clinicopathological study. Muscle Nerve 1997; 20: 846-57.
46. 46 Feasby TE, Hahn AF, Brown WF, et al. Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms? J Neurol Sci 1993; 116: 185-92.
47. 47 Powell HC, Myers RR. The axon in Guillain-Barré syndrome: immune target or innocent bystander? Ann Neurol 1996; 39: 4-5.
48. 48 Cornblath DR, Mellits ED, Griffin JW, et al. Motor conduction studies in Guillain-Barré syndrome: description and prognostic value. Ann Neurol 1988; 23: 354-59.
49. 49 Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986; 109: 1115-16.
50. 1a antibodies. Muscle Nerve 1992; 15: 899-903.
51. 51 Brown WF, Feasby TE, Hahn AF. Electrophysiological changes in the acute "axonal" form of Guillain-Barré syndrome. Muscle Nerve 1993; 16: 200-05.
52. 52 Hafer-Macko C, Hsieh S-T, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996; 40: 635-44.
53. 53 Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol 1996; 25: 33-51.
54. 1 antibodies following Campylobacter enteritis. Neurology 1990; 40: 1900-02.
55. 55 Gregson NA, Jones D, Thomas PK, Willison HJ. Acute motor neuropathy with antibodies to GM1 ganglioside. J Neurol 1991; 238: 447-51.
56. 56 Ho TW, Hsieh ST, Nachamkim I, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 1997; 48: 717-24.
57. 57 Ganser AL, Kirschner DA. Differential expression of gangliosides on the surfaces of myelinated nerve fibres. J Neurosci Res 1984; 12: 245-55.
58. 1b from a patient with motor neuron disease. Neurology 1988; 38: 1890-92.
59. + currents in isolated rat myelinated nerve fibres. Ann Neurol 1995; 37: 436-42.
60. 60 Roberts M, Willison HJ, Vincent A, Newsom-Davis J. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann Neurol 1995; 38: 111-18.
61. 61 Ho TW, Li CY, Cornblath DR, et al. Patterns of recovery in the Guillain-Barré syndromes. Neurology 1997; 48: 695-700.
62. 62 Kornberg AJ, Pestronk A, Blume GM, et al. Selective staining of the cerebellar molecular layer by serum IgG in Miller Fisher and related syndrome. Neurology 1996; 47: 1317-20.
63. 63 Roberts M, Willison H, Vincent A, Newsom-Davis J. Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release. Lancet 1994; 343: 454-55.
64. 64 The Italian Guillain-Barré Study Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients. Brain 1996; 119: 2053-61.
65. 65 Rees JH, Thompson RD, Hughes RAC. An epidemiological study of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1996; 61: 215.
66. 66 Ng KKP, Howard RS, Fish DR, et al. Management and outcome of severe Guillain-Barré syndrome. QJM 1995; 88: 243-50.
67. 67 Bos AP, van der Meché FGA, Witsenburg M, van der Voort E. Experiences with Guillain-Barré syndrome in a pediatric intensive care unit. Intensive Care Med 1987; 13: 328-31.
68. 68 French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22: 753-61.
69. 69 French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Plasma exchange in Guillain-Barré syndrome: one-year follow-up. Ann Neurol 1992; 32: 94-97.
70. 70 Kleyweg RP, van der Meché FGA. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry 1991; 54: 957-60.
71. 71 Rudnicki S, Vriesendorp F, Koski CI, Mayer RF. Electrophysiologic studies in the Guillain-Barré syndrome: effects of plasma exchange and antibody rebound. Muscle Nerve 1992; 15: 57-62.
72. 72 van der Meché FGA, Schmitz PIM, Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-29.
73. 73 Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349: 225-30.
74. 74 Dutch Guillain-Barré Study Group. Treatment of Guillain-Barré syndrome with high-dose methylprednisolone: a pilot study. Ann Neurol 1994; 35: 749-52.